Financial News
Articles published by Apellis Pharmaceuticals, Inc.
Apellis Receives Permanent J-Code (J2781) for SYFOVRE® (pegcetacoplan injection), Effective October 1, 2023
September 25, 2023
Via GlobeNewswire
Tickers
APLS
Apellis Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
September 06, 2023
Via GlobeNewswire
Tickers
APLS
Apellis Pharmaceuticals to Present at Upcoming Investor Conferences
September 05, 2023
Via GlobeNewswire
Tickers
APLS
Via GlobeNewswire
Tickers
APLS
Apellis Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
August 04, 2023
Via GlobeNewswire
Tickers
APLS
Via GlobeNewswire
Tickers
APLS
Apellis Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
July 06, 2023
Via GlobeNewswire
Tickers
APLS
Apellis Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
June 06, 2023
Via GlobeNewswire
Tickers
APLS
Via GlobeNewswire
Tickers
APLS
Via GlobeNewswire
Tickers
APLS
Apellis Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
April 06, 2023
Via GlobeNewswire
Tickers
APLS
Apellis Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
March 06, 2023
Via GlobeNewswire
Tickers
APLS
Via GlobeNewswire
Tickers
APLS
Apellis Pharmaceuticals Announces Pricing of Public Offering of Common Stock and Pre-Funded Warrants
February 22, 2023
Via GlobeNewswire
Tickers
APLS
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.